Combined positive axillary lymph node marking with iodine-125 seeds and sentinel lymph node biopsy in breast cancer patients treated with neoadjuvant chemotherapy

ConclusionesLa colocación de semillas de 125I es una técnica factible para la localización intraoperatoria del ganglio positivo biopsiado en combinación con la BGC. El resultado anatomopatológico del GM permite determinar el estatus axilar posneoadyuvancia.AbstractObjectiveTo present our initial experience in the combined procedure of intraoperative detection of axillary positive node marked with 125I seed (ML) and sentinel node biopsy (SLN) after neoadjuvant chemotherapy (NACT), in breast cancer patients.Material and methodsProspective study, January 2017 – March 2019, 16 breast cancer patients T1-3N1. TNM stage: IIA: 3, IIB: 10, IIIA: 3. Histological type ductal invasive: 14. Molecular subtype: luminal A: 3, luminal B: 9, HER2: 3, basal like: 1.The ML was marked 227 ± 36 days before NACT (n: 10), or 1–6 days before surgery, on previously identified node by ultrasound visibility marker, hydrogel (n: 3) or three dimensional-3D (n: 3). Axillary lymphadenectomy (AD) was undertaken in 10 patients.ResultsML and SLN were identified in the surgery in 93.7 % (15/16) of the cases, in 33.3 % (5/15) ML was not among SLN, and in only one patient (1/5) was there a discrepancy between the result of ML and SLN (macrometastases vs. negative 0/2). Median number of lymph nodes SLN: 2.2 ± 0.9 (range 1–3) and AD: 13.5 ± 5.2 (range 7–23). In all cases, histopathological analysis of ML, 125I seed and/or marker within, correctly predicted axillary stat...
Source: Revista Espanola de Medicina Nuclear e Imagen Molecular - Category: Nuclear Medicine Source Type: research